ENA 2022 Scientific programme

Wednesday 26 October 2022

Clinical Trial Methodology Workshop: The role of ctDNA in clinical trials

10:00 - 12:00  Room 111 + 112

Chair: Saskia Litière (Belgium)
Chair: Marie Morfouace (Belgium)

10:00  ctDNA in clinical trial practice today
Speaker: Marie Morfouace (Belgium)

10:20  ctDNA as a biomarker for patient selection in the neo-adjuvant/adjuvant setting
Speaker: Michail Ignatiadis (Belgium)

10:40  ctDNA as an endpoint in the adjuvant setting
Speaker: Coralie Poncet (Belgium)

11:00  Is there a role for ctDNA in RECIST?
Speaker: Elena Garralda (Spain)

11:20  Panel discussion: ctDNA in clinical trial practice tomorrow
Panel: Saskia Litière (Belgium)
Panel: Marie Morfouace (Belgium)
Panel: Michail Ignatiadis (Belgium)
Panel: Coralie Poncet (Belgium)
Panel: Elena Garralda (Spain)
Panel: Concepcion Biurrun (Spain)
Panel: Vassilis Golfinopoulos (Belgium)

Opening Ceremony: Welcome and opening of the ENA 2022 conference

13:00 - 13:05  Room 111 + 112

Chair: Ruth Plummer (United Kingdom)

Michel Clavel Lecture

13:05 - 13:50  Room 111 + 112

Chair: Ruth Plummer (United Kingdom)

Cancer Initiation, Immune Evasion and Metastases: Insights from TRACERx
Keynote Speaker: Charles Swanton (United Kingdom)
Keynote Lecture

13:50 - 14:35
Room 111 + 112

Chair: Lillian L. Siu (Canada)

Clinical and translational advances in cancer immunotherapeutics
Keynote Speaker: Lisa Butterfield (USA)

Plenary Session 1: STING Agonists

14:45 - 16:15
Room 111 + 112

Chair: Samuel Bakhoum (USA)
Chair: Ignacio Melero (Spain)

14:45
Local immunotherapy: translation of the dsRNA analog BO112
Speaker: Ignacio Melero (Spain)

15:05
An orally available non-nucleotide STING agonist with antitumor activity: A mechanistic study
Speaker: Gottfried Schroeder (USA)

15:25
E7766
Speaker: Kim Dae-Shik (USA)

15:45
Sting agonists early phase study
Speaker: Funda Meric-Bernstam (USA)

16:05
Q&A

Mini Symposium: ADC variety

16:15 - 17:45
Room 111 + 112

Chair: Aditya Bardia (USA)
Chair: Valentina Boni (Spain)

Antibody drug conjugates - beyond cytotoxic payloads
Speaker: Andrew Souers (USA)

Antibody-drug conjugates and ISACs
Speaker: Anthony W. Tolcher (USA)

Novel ADCs
Speaker: Shyra Gardai (USA)

ADC prodrugs
Speaker: Valentina Boni (Spain)

Mini Symposium: Drug Development of Mutant Specific versus Target Selective Inhibitors

16:15 - 17:45
Room 211 + 212

Chair: Elena Garralda (Spain)
Chair: Udai Banerji (United Kingdom)
Thursday 27 October 2022

Plenary Session 2: Allogeneic Genetically Engineered Cells for ACT

08:00 - 09:30 Room 111 + 112

Chair: David Quach (USA)
Chair: Denis Migliorini (Switzerland)

08:00 ‘off-the-shelf’ Allogeneic CAR T cells: development and challenges
Speaker: Stéphane Depil (France)

08:20 Allogeneic CAR T cells: An alternative to overcome challenges of CAR T cell therapy in glioblastoma
Speaker: Denis Migliorini (Switzerland)

08:40 Expansion and persistence of allogeneic therapeutic T-cells via expression of a CD30.CAR
Speaker: David Quach (USA)

09:00 Genetically engineered NK therapy for immunotherapy-resistant cancers
Speaker: Rafet Basar (USA)

09:20 Q&A

Plenary Session 3: Proffered Papers

10:00 - 11:30 Room 111 + 112

Plenary Session 4: Emerging New Targets

11:30 - 13:00 Room 111 + 112

Chair: James L. Gulley (USA)
Chair: Christophe Le Tourneau (France)

11:30 Mannose receptor and innate antitumor immunity
Speaker: Udo Rudloff (USA)
AACR-Chemistry in Cancer Research Working Group (CICR) Town Hall Meeting and Networking Reception

Room 211 + 212

Workshop 1: Drug development in low-middle income countries - challenges and opportunities

15:00 - 16:30

Chair: Daniel Araujo (Brazil)
Chair: Bishal Gyawali (Canada)

15:00  
Clinical research environment in Latin-America and opportunities for drug development  
Speaker: Daniel Araujo (Brazil)

15:15  
The national cancer grid of India - impact in oncology research  
Speaker: C.S. Pramesh (India)

15:30  
Challenges and opportunities for drug development in Asia  
Speaker: Herbert Loong (Hong Kong)

15:45  
Advantages and pitfalls of drug development in LMIC  
Speaker: Bishal Gyawali (Canada)

16:00  
Reducing disparities in eligibility for cancer immunotherapy clinical trials for people living with HIV  
Speaker: Thomas Odeny (USA)

16:15  
Discussion

Workshop 2: Using ctDNA in directing therapy of advanced cancer

15:00 - 16:30

Chair: Lillian L. Siu (Canada)
Chair: Alberto Bardelli (Italy)

15:00  
Circulating tumor ctDNA analysis to direct therapy for breast cancer (plasmaMATCH)  
Speaker: Nick Turner (United Kingdom)
15:15 ctDNA in metastatic MSI-H cancers  
Speaker: Francois-Clement Bidard (France)

15:30 Circulating tumor DNA analysis in the development of new drugs for advanced GI cancer  
Speaker: Takayuki Yoshino (Japan)

15:45 ctDNA guiding immunotherapy in urothelial carcinoma  
Speaker: Bernadett Szabados (United Kingdom)

16:00 Discussion

Workshop 3: AI and Computational Analysis

17:00 - 18:30 Room 111 + 112

Chair: Pedro Cutillas (United Kingdom)  
Chair: Eric Stahlberg (USA)

17:00 ATOM  
Speaker: Eric Stahlberg (USA)

17:15 Computational genomics  
Speaker: Eytan Ruppin (USA)

17:30 Computational biology  
Speaker: Lopes-Bigas (Spain)

17:45 Academic perspective clinical trials  
Speaker: Emiliano Calvo (Spain)

18:00 Discussion

Workshop 4: Liquid biomarker and Single-Cell Analysis in cancer research

17:00 - 18:30 Room 211 + 212

Chair: Minetta Liu (USA)  
Chair: Takayuki Yoshino (Japan)

17:00 Liquid biomarker for early detection  
Speaker: Minetta Liu (USA)

17:15 Liquid biomarker for stratification in clinical trials  
Speaker: Takayuki Yoshino (Japan)

17:30 Liquid biomarkers for cancer characterization and monitoring  
Speaker: Maximilian Diehn (USA)

17:45 MRD and different ctDNA technologies  
Speaker: Marc Oliva (Spain)

18:00 Discussion
Friday 28 October 2022

Plenary Session 5: Project Optimus from the FDA: how will this affect clinical trials and drug development?

08:00 - 09:30 Room 111 + 112

Chair: Lesley Seymour (Canada)
Chair: Josep Tabernero (Spain)

08:00 Project Optimus guidance from FDA
Speaker: Mirat Shah (USA)

08:15 Clinical pharmacology perspective
Speaker: Mark J. Ratain (USA)

08:30 Clinical trialists' perspective
Speaker: Josep Tabernero (Spain)

08:45 Dose selection for oncology drugs- a critical choice
Speaker: Susan Galbraith (United Kingdom)

09:00 Panel Discussion
Panel: Lesley Seymour (Canada)
Panel: Josep Tabernero (Spain)
Panel: Mirat Shah (USA)
Panel: Mark J. Ratain (USA)
Panel: Susan Galbraith (United Kingdom)
Panel: Inez Font Rodriguez (Spain)

Workshop 5: Modernising eligibility criteria for early phase oncology clinical trials

10:00 - 11:30 Room 111 + 112

Chair: S. Percy Ivy (USA)
Chair: Emiliano Calvo (Spain)

10:00 Why should eligibility criteria for early phase trials be broadened?
Speaker: Emiliano Calvo (Spain)

10:10 Overview of the ASCO/friends of cancer research process for modernizing eligibility criteria and how their findings devolved to clinical practice
Speaker: S. Percy Ivy (USA)

10:20 Performance status vs. fitness tools, is one better than the other?
Speaker: Heidi Klepin (USA)

10:30 How changes in evaluation of renal function affect early phase trial eligibility
Speaker: Jan Beumer (USA)

10:40 Trial pathfinder, data-driven approach to broaden restrictive eligibility criteria using artificial intelligence
Speaker: Ruishan Liu (Canada)

10:50 Generalizability of modernized eligibility criteria to achieve inclusiveness in clinical trials
Speaker: Olga Kholmanskikh (Belgium)

11:00 Panel discussion
Moderator: Jaap Verweij (Netherlands)
Workshop 6: How to optimize the use of preclinical models for drug development

10:00 - 11:30
Room 211 + 212

Chair: Chris Lord (United Kingdom)
Chair: Emile Voest (Netherlands)

10:00     Ex-vivo avatars to understand immune checkpoint blockade mechanism of action
Speaker: Daniela Thommen (Netherlands)

10:15     High-throughput drug sensitivity and CRISPR screens
Speaker: Chris Lord (United Kingdom)

10:30     Organoids as preclinical model for drug discovery
Speaker: Emile Voest (Netherlands)

10:45     Deciphering the spatiotemporal control of tumor immune phenotype by live imaging
Speaker: Christine Moussion (USA)

11:00     Discussion

Plenary Session 6: New Drugs on the Horizon

11:30 - 13:00
Room 111 + 112

Chair: Timothy Yap (USA)
Chair: Elena Garralda (Spain)

11:30     Cancer cachexia target
Speaker: Marcus DaSilva Goncalves (USA)

11:40     T cell engager and NK cell engager
Speaker: Elizabeth Budde (USA)

11:50     Personalized cancer vaccines
Speaker: Patrick Ott (USA)

12:00     MTH1, DUBs
Speaker: Thomas Helleday (Sweden)

12:10     Molecular glue/degraders
Speaker: Filip Janku (USA)

12:20     Abstract slot

12:30     Abstract slot

12:40     Discussant: To be announced ()

Plenary Session 7: Late Breaking Proffered Paper

15:00 - 16:30
Room 111 + 112